Synaptogenix, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Evoke Pharma, Inc.

Jaguar Health, Inc.

Tempest Therapeutics, Inc.

Synaptogenix, Inc.

Kiora Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

Artelo Biosciences, Inc.

ZyVersa Therapeutics, Inc.

CNS Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

Universe Pharmaceuticals, Inc.

Why is Synaptogenix, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Synaptogenix, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Synaptogenix, Inc.

108.14%

0.29

149.30%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.89%

EBIT Growth (5y)

6.99%

EBIT to Interest (avg)

-11.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.87

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.58%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.86

EV to EBIT

-4.20

EV to EBITDA

-4.20

EV to Capital Employed

-30.92

EV to Sales

30.92

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-40.86%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

NET SALES(9M)

At USD 0.21 MM has Grown at inf%

NET PROFIT(HY)

Higher at USD -3.91 MM

RAW MATERIAL COST(Y)

Fallen by -9,961% (YoY

-6What is not working for the Company

NET PROFIT(HY)

At USD -3.91 MM has Grown at -32.66%

ROCE(HY)

Lowest at -180.52%

CASH AND EQV(HY)

Lowest at USD 35.69 MM

DEBT-EQUITY RATIO (HY)

Highest at -100.95 %

Here's what is working for Synaptogenix, Inc.

Net Sales

At USD 0.21 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Net Profit

Higher at USD -3.91 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Raw Material Cost

Fallen by -9,961% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Synaptogenix, Inc.

Net Profit

At USD -3.91 MM has Grown at -32.66%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 35.69 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -100.95 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio